Entrada Therapeutics Receives Authorization in the United Kingdom to Initiate ELEVATE-44-201, a Phase 1/2 Multiple Ascending Dose Clinical Study of ENTR-601-44 in Patients Living with Duchenne Muscular Dystrophy
Provided By GlobeNewswire
Last update: Feb 3, 2025
– Company on track to initiate ELEVATE-44-201 in Q2 2025 –
– ENTR-601-44 regulatory filings submitted in additional geographies including the U.S. and EU, with regulatory discussions ongoing –
Read more at globenewswire.com
